



ASX and Media Release

Viralytics Announces Formation of Clinical Advisory Board

22 November 2016, Sydney, Australia: [Viralytics Limited](#) (ASX: VLA, OTCQX: VRACY) today announced that it has formed a Clinical Advisory Board (CAB) to serve as a strategic resource to the company as it continues to broaden and advance the clinical development program for its lead drug candidate, [CAVATAK™](#). CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells.

"This international team of experts in the clinical development of new cancer therapies brings a wealth of valuable insight and experience to our efforts to accelerate CAVATAK's progress in the clinic," stated Dr Malcolm McColl, Managing Director and Chief Executive Officer of Viralytics. "We look forward to working with this distinguished group as we advance CAVATAK in multiple clinical trials as a potential treatment for a range of cancer types, both as a single agent and in combination with other promising immunotherapies."

Viralytics' newly established CAB will be chaired by **Keith Flaherty, MD**, Professor of Medicine at Harvard Medical School and Director of the Termeer Center for Targeted Therapy and Director of Clinical Research at the Massachusetts General Hospital Cancer Center. Dr Flaherty, who previously served on Viralytics' Scientific Advisory Board, has been the principal investigator for numerous clinical trials with a focus on exploring novel targeted therapies in cancer. In these trials, he focused on the development of response and predictive biomarkers to define the mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population.

Also joining the new CAB is **Michael Boyer, MD, PhD**, Professor of Medical Oncology at the Sydney Medical School, the University of Sydney and Chief Clinical Officer of the Chris O'Brien Lifehouse. Dr Boyer is a medical oncologist with clinical interests in the management of thoracic malignancies and head and neck cancers. His major research focus is on the clinical development of new agents for the management of lung cancer and mesothelioma. The author of over 145 publications and a frequent presenter at national and international conferences, Dr Boyer is actively involved in the lung cancer community. He chaired the scientific advisory committee of the Australasian Lung Cancer Trials Group between 2004 and 2011, and was the conference Co-President for the 15th World Conference on Lung Cancer held in Sydney in 2013. He is currently a member of the Board of Directors of the International Association for the Study of Lung Cancer.



J. Randolph Hecht, MD, Professor of Clinical Medicine at the David Geffen School of Medicine at UCLA, is the third member of Viralytics' CAB. Dr Hecht holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is also the Director of the UCLA Gastrointestinal Oncology Program. He is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. Dr Hecht has led and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and major phase II and phase III trials with novel agents.

The fourth member of the CAB is **Kurt Schalper, MD, PhD**, Assistant Professor of Pathology at the Yale School of Medicine and Director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center. As a leader in translational cancer research, Dr Schalper is focused on leveraging advances in targeted therapy and immunotherapy to develop new treatments that will improve outcomes for cancer patients. He is a member of a Stand Up To Cancer - American Cancer Society Dream Team formed to discover novel, targeted immunological approaches to treating KRAS-mutant lung cancers. At Yale, he has also developed new objective, quantitative, and reproducible assays for measuring anti-tumour immune responses in human solid tumours – an advance that could lead to novel predictive biomarkers and immunostimulatory therapies.

About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Robert Vickery
Chief Financial Officer
02 9988 4000